Conference Coverage
Latest News
Sep 05, 2025 | News
CGTLive®’s Weekly Rewind – September 5, 2025
Robert Alexander Wesselhoeft, PhD, on the Therapeutic Potential of Circular RNA
Sep 05, 2025
Nanoscope Nabs RMAT Designation for Retinitis Pigmentosa Gene Therapy MCO-010
Sep 04, 2025
Preclinical Evidence for PH1 Gene Therapy
Sep 03, 2025
Around the Helix: Cell and Gene Therapy Company Updates – September 3, 2025
Sep 03, 2025
Advertisement
Shorts
1:02
Innovative Treatment Considerations for CAR-T Therapies
Stephen J. Schuster, MD, discussed the use of fractionated CAR-T in patients with progressive disease.
9 days ago
by
Stephen J. Schuster, MD, Abramson Cancer Center
0:47
The Importance of Nonmyeloablative Chemotherapy to Cell Therapy
Michael T. Lotze, MD, discussed one of the major advances enabling the practicality of cell therapy in oncology.
9 days ago
by
Michael T. Lotze, MD
0:25
Which Therapy Predicts a Better Response to TIL in Melanoma?
Michael T. Lotze, MD, quizzed Joseph Fraietta, PhD, on therapies that have predictive potential on outcomes for subsequent tumor infiltrating lymphocyte (TIL) therapy.
9 days ago
by
Michael T. Lotze, MD
0:58
Marcela Maus, MD, PhD on Autologous vs. Allogenic Therapies
Janna Minehart, MD, asks Marcela Maus, MD, PhD, for her most controversial opinion on CAR-T therapies.
9 days ago
by
Marcela V. Maus, MD, PhD(+1 more)
1:02
Unexpected Results in CAR T Cell Therapy Study in Glioblastoma
Marcela Maus, MD, PhD, discusses some of the exciting results of CAR-T therapy in a glioblastoma trial.
9 days ago
by
Marcela V. Maus, MD, PhD
1:30
The History and Evolution of CAR T Cell Therapy
Marcela Maus, MD, PhD, shares her knowledge on the history and evolution of CAR-T cell therapy.
9 days ago
by
Marcela V. Maus, MD, PhD
Podcasts
Videos
Advertisement
All News
Advertisement
The chief scientific officer and senior director of preclinical pharmacology Arbor Biotechnologies discussed ABO-101, the company’s gene therapy for primary hyperoxaluria type 1.
The rAAVrh8 gene therapy delivers HEXA and HEXB genes and has posted positive phase 1/2 results in infantile GM2 gangliosidosis, with enhancements in enzymatic activity and neurological outcomes.
Catch up on any of the key FDA news stories you may have missed last month, with coverage highlights from the CGTLive® team.
Review top news and interview highlights from the week ending August 29, 2025.
Annaiz Grimm, BS, a research scientist at Seattle Children's Research Institute, discussed the potential use of EngTregs to treat autoimmune disease.
The research scientist at Seattle Children's Research Institute discussed a potential alternative to standard of care immunosuppressive therapy.
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
Prerna Mewawalla, MD, the medical director of Apheresis and a hematologist-oncologist in the Division of Hematology and Cellular Therapy at Allegheny Health Network, spoke on unmet needs in patients who receive early-line CAR-T for R/R MM.
Notably, the FDA granted Papzimeos a full approval, without a requirement for a confirmatory trial.
Ultragenyx anticipates that the full BLA will have been submitted in the fourth quarter of this year.
Advertisement
The medical director of Apheresis and a hematologist-oncologist in the Division of Hematology and Cellular Therapy at Allegheny Health Network spoke about unmet needs in patients who receive early-line CAR T for R/R MM.
The new PDUFA date is set for February 8, 2026.
Surbhi Sidana, MD, the assistant professor of medicine, bone marrow transplantation, and cellular therapy at Stanford discussed the benefit of second-line cilta-cel in PFS and OS.
Review top news and interview highlights from the week ending August 22, 2025.
The hold was originally placed on the trial by the FDA on May 23, 2025, following the death of a patient treated in the study.
Advertisement
Advertisement
